Nicotine-Mediated Cell Proliferation and Tumor Progression in Smoking-Related Cancers

Courtney Schaal and Srikumar P. Chellappan

Abstract

Tobacco smoke contains multiple classes of established carcinogens including benzo(a)pyrenes, polycyclic aromatic hydrocarbons, and tobacco-specific nitrosamines. Most of these compounds exert their genotoxic effects by forming DNA adducts and generation of reactive oxygen species, causing mutations in vital genes such as K-Ras and p53. In addition, tobacco-specific nitrosamines can activate nicotinic acetylcholine receptors (nAChR) and to a certain extent β-adrenergic receptors (β-AR), promoting cell proliferation. Furthermore, it has been demonstrated that nicotine, the major addictive component of tobacco smoke, can induce cell-cycle progression, angiogenesis, and metastasis of lung and pancreatic cancers. These effects occur mainly through the α7-nAChRs, with possible contribution from the β-ARs and/or epidermal growth factor receptors. This review article will discuss the molecular mechanisms by which nicotine and its oncogenic derivatives such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane and N-nitrosornicotine induce cell-cycle progression and promote tumor growth. A variety of signaling cascades are induced by nicotine through nAChRs, including the mitogen-activated protein kinase/ extracellular signal-regulated kinase pathway, phosphoinositide 3-kinase/AKT pathway, and janus-activated kinase/STAT signaling. In addition, studies have shown that nAChR activation induces Src kinase in a β- Arrestin-1-dependent manner, leading to the inactivation of Rb protein and resulting in the expression of E2F1-regulated proliferative genes. Such nAChR-mediated signaling events enhance the proliferation of cells and render them resistant to apoptosis induced by various agents. These observations highlight the role of nAChRs in promoting the growth and metastasis of tumors and raise the possibility of targeting them for cancer therapy. Mol Cancer Res; 12(1); 14–23. ©2014 AACR.

Introduction

Lung cancer is the leading cause of cancer-related deaths worldwide for both men and women, exceeding that of breast, prostate, and colon cancer combined (1). Smoking is by far the greatest and most preventable risk factor for lung cancer, accounting for approximately 70% of non–small cell lung cancer (NSCLC) cases and 90% of small cell lung cancer (SCLC) cases (2), although there is a subset of patients who develop lung cancer without a history of smoking (3). Tobacco smoke contains multiple classes of carcinogens such as polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and aldehydes that are capable of initiating tumorogenesis (2, 4–6), primarily through the formation of DNA adducts resulting in mutations of vital genes such as KRAS, p53, and Rb (7). Nicotine, which is the addictive component of tobacco smoke, is unable to initiate tumorigenesis in humans and rodents; at the same time, nicotine has been shown to promote tumor growth and metastasis by inducing cell-cycle progression, epithelial-to-mesenchymal transition (EMT), migration, invasion, angiogenesis, and evasion of apoptosis in a variety of systems (8–13). In addition, nicotine has been shown to induce secretion of growth factors and cytokines altering the physiology of multiple organ systems (8–13). These observations suggest that nicotine likely contributes to the progression and metastasis of tumors that are initiated by tobacco carcinogens.

Nicotine is thought to promote tumor progression through the binding to and activation of cell-surface receptors, especially nicotinic acetylcholine receptors (nAChR), and to a certain extent β-adrenergic receptors (β-AR; refs. 14–16). In addition to nicotine, its oncogenic derivatives 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane (NNK) and N-nitrosornicotine (NNN) present in tobacco smoke can bind to and activate nAChRs, stimulating multiple cancer-promoting signaling cascades (16, 17). The mutagenic effects of tobacco-specific nitrosamines are mainly mediated by diffusion through the cell membrane in a receptor-independent fashion (18); at the same time, the signaling events induced by these agents through nAChRs are also thought to contribute...
to the concentration observed in the bloodstream of smokers have ranged from 10 nmol/L to 10 μmol/L and can spike to 10 μmol/L or more immediately after smoking (26, 27). Similar results to those obtained in vitro have also been demonstrated in in vivo mouse models of lung cancer, where nicotine significantly increased the size and number of tumors in the lung, and enhanced metastasis (11). Comparable results have been reported in the case of pancreatic cancer as well (10, 28, 29).

Additional support for the correlation between nAChRs, smoking, and cancer was obtained from genome-wide association studies (GWAS), which identified a lung cancer susceptibility locus on chromosome 15q24-25. Polymorphisms in this region correlated with increased risk for lung cancer development, nicotine dependence, and number of cigarettes smoked per day (30). 15q24-25 contains CHRNA3, CHRNA5, and CHRNA4 genes that encode α7 nAChR, which has been implicated as the primary receptor involved in smoking addiction, and has more recently been associated with smoking behavioral patterns (31). Furthermore, a nonsynonymous variation in CHRNA5 (D398N) is strongly associated with increased lung cancer risk (31).

Although nAChRs are the primary receptors through which nicotine exerts its effects, β-ARs and epidermal growth factor receptors (EGFR) are also thought to play a role (17, 33, 34). It has been suggested that nAChRs might functionally network with β-AR and EGFR, and all 3 receptors frequently coexist on human lung cancer cells, airway endothelial cells, and airway epithelial cells (35). Nicotine binds to α7 nAChRs inducing the secretion of growth factors such as EGF, neurotransmitters such as adrenaline and noradrenaline, and angiogenic factors such as VEGF (34). The nicotine-mediated secretion of EGF via nAChRs results in the transactivation of EGFR, leading to the activation of mitogenic and antiapoptotic pathways (16, 36). Similarly, the nicotine-mediated release of adrenaline and noradrenaline, which are the physiologic ligands for β-AR, leads to the binding to and activation of β-AR, which in turn activates proliferative pathways and the release of EGF, VEGF, and arachidonic acid, which contribute to the development and progression of lung cancer (37). Interestingly, nicotine and NNK have been shown to bind to β-ARs as well, stimulating multiple oncogenic and mitogenic signaling cascades (17, 22, 37). This cooperative interplay between these receptors can be expected to have significant mitogenic effects on cell-cycle machinery, contributing to the oncogenic process. The interplay between the different receptors that respond to nicotine and its derivatives is shown in Fig. 1.

**Induction of ERK/MAPK signaling cascade by nAChRs**

A number of studies have been conducted to elucidate the molecular mechanisms involved in nicotine and nitrosamine-mediated cell proliferation, and these have revealed the involvement of multiple signaling cascades downstream of the nAChRs; the major pathways are depicted in Fig. 2. One signaling cascade that is induced by nAChRs across various cell types is the mitogen-activated protein kinase (MAPK) cascade, which is known to facilitate cell proliferation in a wide variety of tumor types. For example, stimulation of...
SCLC cells with nicotine was found to induce the MAPK cascade in a dose-dependent fashion; this was diminished upon treatment with the nAChR inhibitor mecamylamine (38). Similar results were reported in another study on SCLC and NSCLC cells, where proliferation was increased and MAPK signaling was activated in response to nAChR stimulation; interestingly, this study demonstrated that the ERK2 isoform is specifically activated in response to nicotine. This activation of ERK2 occurs concomitantly, albeit separately, to the activation of protein kinase C (PKC), as seen by a combination of Western blotting experiments and MAP kinase assays (39). Multiple studies done on human and murine lung cancer cells have further demonstrated that PKC activity was increased in response to nicotine, and was activated independent of the Ras pathway (12, 40–42). In addition, it was demonstrated that nicotine had no apparent effect of the levels of the MAPK family members p38 or JNK, or on the MAPK phosphatases PAC1 and MKP-1, indicating that these had lesser roles in nicotine-mediated activation of MAPK signaling (39). Comparable to this finding on nicotine stimulation, it was found that stimulation of SCLC cells or neuroendocrine cells with the nitrosoamine NNK resulted in increased DNA synthesis and proliferation, as well as activation of Raf-1 kinase; this activation could be blocked by inhibition of PKC or by the α7 nAChR antagonist α-BT (43). These results indicate that the observed effects were mediated through the α7 receptor, and that PKC acts upstream of Raf-1 in this signaling sequence (43). Furthermore, it was demonstrated that NNK stimulation increased the expression of c-Myc protein, suggesting that c-Myc is another target upregulated by NNK, probably through the activation of the MAPK cascade (43). A number of additional studies have validated these results, demonstrating that nicotine and NNK activate the MAPK cascade to induce cellular proliferation, and this can be inhibited by α-BT, indicating that this chain of events is mediated specifically by the α7 nAChR. This is true for both cancer cells as well as normal cells (15, 36, 44).

**nAChR-mediated activation of Src and the Rb-E2F pathway**

The above studies collectively demonstrate the ability of nicotine and NNK to induce the MAPK signaling cascade through the activation of nAChRs; however, unlike growth factor receptors, nAChRs do not possess intrinsic kinase activity (45, 46). A study designed to understand how α7-nAChRs induce MAPK cascade and promote cell proliferation demonstrated that the scaffolding protein β-arrestin-1 is recruited to the receptor upon nicotine stimulation and this recruitment was necessary for the further recruitment and activation of Src Kinase (47). Src family kinases are known to facilitate signaling from cell surface receptors that lack intrinsic kinase activity and inhibition or depletion of Src could prevent nAChR-mediated cell proliferation (47).
study further demonstrated that the activation of Src upon nAChR stimulation leads to the direct binding of the Raf-1 kinase to the Rb tumor suppressor protein, preceding the cyclin-cdk-mediated inactivation of Rb. In vitro kinase assays showed an increase in the activity of kinases associated with cyclins D and E when cells were stimulated with 1 μmol/L nicotine; furthermore, chromatin immunoprecipitation assays showed that Rb dissociated from proliferative promoters such as Cdc6 and Cdc25A upon nicotine stimulation, leading to their expression (47). The binding of Raf-1 to Rb is thought to facilitate the inactivation of Rb by cyclins and cdks, and Raf-1–Rb interaction was found to be elevated in NSCLC tumor samples compared with adjacent normal tissue, indicating a predominant role for β-arrestin-1 in nicotine-mediated activation of these signaling events (51). The same study investigated the sequence of signaling events induced by nicotine, and it was found that phospho-Src levels were increased within 5 minutes of nicotine stimulation, whereas phospho-AKT1 and phospho-ERK1/2 levels increased after 15 minutes, suggesting that the latter 2 kinases are activated subsequent to Src activation (51). It was additionally found that a subset of β-arrestin-1 molecules translocate into the nucleus upon nicotine stimulation where it physically associates with E2F1; β-arrestin-1 recruited the histone acetyl transferase p300 to E2F-regulated proliferative and prosurvival promoters, facilitating histone H3 acetylation and gene expression (51). The potential role for β-arrestin-1 in lung tumorigenesis was further suggested by the detection of elevated levels of β-arrestin-1 on proliferative promoters in human tumor samples compared with adjacent normal tissues. These observations reveal that activation of the Rb-E2F cascade is a major consequence of the nAChR-mediated signaling events and that β-arrestin-1 contributes to this process significantly. The involvement of β-arrestin-1 also suggests an additional functional link between nAChRs and G-protein–coupled receptors such as β-ARs and opioid

Figure 2. A schematic representing nAChR signaling cascades in lung cancer. NNK and nicotine found in tobacco smoke bind to nAChRs with high affinity and induce multiple signaling cascades resulting in cycle progression, proliferation, and survival. Upon activation of nAChRs by ligand binding, β-arrestin-1 is recruited to the receptor and is necessary for further recruitment of Src kinase, which in turn initiates Raf-1 and PI3K/AKT signaling cascades. NNK and nicotine-mediated nAChR activation have also shown to induce signaling cascades such as JAK/STAT and Ras/Raf/MEK, and decrease the levels of cell-cycle inhibitors such as p16INK4 and Cip/Kip proteins.
receptors upon exposure to nicotine, which might have a significant impact on the growth of lung cancer in smokers.

**Induction of the JAK-STAT pathway by nAChR signaling**

In addition to activation of the MAPK and Rb-E2F pathways, it has been observed that nicotine stimulation results in the activation of the JAK-STAT signaling pathway and its target genes, which are altered in multiple cancer types (29, 52, 53). In a study conducted on oral keratinocytes, stimulation of cells with physiologically relevant concentrations of either nicotine or sidestream cigarette smoke resulted in increased STAT3 mRNA and protein levels; these levels were diminished if the cells were pretreated with the α7 nAChR-specific inhibitor α-BT, or if α7 nAChR was depleted using siRNA (54). Further experiments utilizing specific pathway inhibitors revealed that the α7-dependent upregulation of STAT3 occurred through activation of the Ras-Raf-1-MEK-ERK pathway, as well as through the activation of JAK2, indicating the involvement of 2 complementary pathways (54). In α7 null mouse cells, nicotine was unable to induce Ras-mediated activation of STAT3, further demonstrating that this signaling event is mediated through the α7 nAChR (54). In a separate study done on NSCLC, stimulation with physiologically relevant concentrations of nicotine or NNK resulted in increased phospho-STAT3 levels, leading to an induction of the STAT3 target IKBKE (53). Src kinase is known to activate the JAK-STAT pathway in multiple systems, and nicotine was shown to activate Src kinase, which in turn activated the JAK/STAT pathway signaling in cooperation with MEK/ERK1/2 pathway resulting in increased proliferation of pancreatic cancer cells (29). In the same study, nicotine stimulation resulted in increased expression of phospho-JAK2 and enhanced activation of STAT3 through phosphorylation at Y705 in a dose-dependent manner, whereas total STAT3 levels remained unchanged. These effects were abrogated by treatment with the antagonist α-BT, indicating that the signaling was mediated by α7 nAChR (29). It was further demonstrated that nicotine stimulation resulted in an ERK1/2-mediated increase in STAT3 phosphorylation at S727, and this could be reversed by treatment with an ERK inhibitor (29). Immunohistochemical staining of tumors from pancreatic mouse xenograft studies supported these findings, showing increased phosphorylation of STAT3 at Y705 in mice exposed to cigarette smoke (29). Nicotine stimulation was shown to activate STAT3 via nAChRs as well as β-ARs in bladder cancer cells, leading to overexpression of cyclin D1 driving cell-cycle progression, resulting in reduced sensitivity to chemotherapy which could be restored by depletion of STAT3 (55). These studies clearly suggest a role for the JAK-STAT pathway in mediating the proliferative functions of nAChRs.

**Upregulation of cell-cycle regulatory molecules by nAChRs**

In addition to inducing multiple mitogenic signaling events, nicotine and nitrosamines have been shown to target various components of the cell-cycle machinery itself. Numerous studies have shown that the expression of cyclins as well as proteins involved in cell-cycle checkpoints are impacted by nicotine and other components of tobacco smoke. In this context, increased expression of cyclin D1 in response to nicotine stimulation has been reported frequently in the literature (47, 56, 57). Initial studies conducted on mouse lung epithelial cells demonstrated the ability of nicotine to induce cyclin D1 promoter as well as protein expression through nAChR-mediated induction of Ras signaling and activation of its downstream effectors Raf/MAPK (58). It was further demonstrated that Ras activation of c-Jun, which is part of the AP-1 transcription factor complex, binds to the cyclin D1 promoter and is necessary for its nicotine-mediated induction (58). The upregulation of cyclin D1 in response to nicotine was shown to occur concomitantly with an increase in Rb phosphorylation and E2F transcriptional activity (58), promoting the cell-cycle progression of lung epithelial cells. nAChR-mediated proliferation via upregulation of cyclin D1 has additionally been reported in mouse pre-osteoblasts (59). In normal human lung epithelial cells, nicotine and NNK have been shown to upregulate cyclin D1 through the ERK1/2-mediated activation of the NF-κB, and this signal transduction is facilitated via nAChRs (60). Similar results have been reported in human NSCLC cells, where nAChR activation by nicotine stimulation led to an induction of cyclin D-ckd4 and cyclin E-cdk2 kinase activity and Rb phosphorylation, resulting in dissociation of Rb from E2F1 and the induction of E2F1-regulated proliferative genes, including Cdc25A and Cde6 (47, 57). In addition, nicotine and NNK facilitate cell-cycle progression via nAChR and β-AR–mediated induction of COX2 and prostaglandin E2 (PGE2), with an associated increase in cyclin D1 and cdk4/6 expression and Rb phosphorylation (61).

**Suppression of cell-cycle inhibitors by nicotine and NNK**

It has been established that components of tobacco smoke can also repress negative regulators of cell-cycle progression, such as cdk inhibitors (CDKis; refs. 56 and 62). CDKis act to regulate cdk activity and are divided into 2 classes: the INK4 inhibitors including p16, p15, p19, and p18; and the Cip/Kip inhibitors including p21 and p27 (56, 62). Both CDKi types are capable of arresting cells in G1 phase by inhibition of cdks, preventing their phosphorylation of Rb and thus halting cell-cycle progression (56, 62). In human gastric cancer cells, p53, p21, and p27 expression levels are significantly reduced in response to nicotine or NNK stimulation (61). In NSCLC cell lines, nicotine has been shown to induce the transcriptional repressor, ID1, in a Src-dependent manner through the α7-nAChR (34). ID1 is known to induce proliferation by inhibiting the transcription of CDKis p16, p21, and p27, preventing their normal growth suppressive effect (63). This data imply that tobacco smoke not only activates components driving cell-cycle progression, but also inhibits components that arrest cell cycle.

In addition, it has also been shown in murine and human lung epithelial cells that nicotine acts to compromise activation of normal DNA damage checkpoint response at
G1→S, but not the G2→M checkpoint (64). DNA damage check point is activated after exposure to γ-radiation or the tobacco carcinogen benzo(a)pyrene, which induces DNA double-strand breaks; however, when exposed to nicotine, growth restriction was attenuated because of an increase of cyclins D and A, and a decrease in the phosphorylation of the checkpoint kinase 2 (Chk2; ref. 64). Typically, ATM and ATR protein kinases are activated in response to double- or single-stranded DNA breaks respectively, and they stimulate downstream effectors involved in DNA damage checkpoint response including p53, Chk1, Chk2, and H2AX (62). Activation of these proteins results in cell-cycle arrest and DNA repair, or if the damage is beyond repair apoptosis will be induced (62). Once activated, Chk2 phosphorylates Cdc25A phosphatase, preventing it from dephosphorylating and thus activating its target cdk2, resulting in cell-cycle arrest (62). The decrease in Chk2 in lung epithelial cells exposed to nicotine suggests that nicotine may be capable of overriding DNA damage checkpoint activation, disrupting genetic surveillance and increasing the risk of oncogenesis (62, 64). These studies show that nicotine as well as tobacco smoke components can modulate multiple components of the cell-cycle machinery, facilitating cell-cycle progression.

**Regulation of survival pathways by nAChRs—antiapoptotic effects of nicotine**

Although tobacco smoke carcinogens initiate tumors, the current literature raise the possibility that nicotine additionally confers a survival advantage to already initiated tumors (28, 57, 65, 66) by promoting cell-cycle progression and by preventing apoptosis (66, 67). This is of particular concern in the context of tobacco smoke components conferring resistance to chemotherapeutic drugs (66, 67) as well as radiation (68). Multiple studies have reported that patients who smoke demonstrate poor response to cancer chemotherapy, and have worse prognosis than their non-smoking counterparts (65, 69, 70). In this context, many attempts have been made to elucidate the prosurvival and antiapoptotic effects of nAChR signaling.

The phosphoinositide 3-kinase (PI3K)/AKT pathway is a major cancer-associated signaling network that is activated by exposure to nicotine and tobacco carcinogens (71–75). The serine/threonine kinase AKT is a known regulator of key cellular processes such as cell-cycle progression, as well as cell survival (71, 75). Both nicotine and NNK were found to induce AKT phosphorylation at S473 and T308 in a time- and dose-dependent manner in normal human bronchial epithelial cells and small airway epithelial cells (71). This effect was evident as early as 5 minutes after nicotine stimulation and at a range of physiologically relevant concentrations, from 10 nmol/L to 10 mMol/L; however, response to NNK was not apparent for 15 minutes but was seen at concentrations as low as 1 nmol/L (71). Similarly, downstream substrates of AKT involved in cell-cycle progression including GSK-3β, FKHR, and 4EBP-1 were all induced by nicotine, whereas GSK3-α and 4EBP-1 were induced by NNK (71). Furthermore, this response could be abrogated by the PI3K inhibitor and by the α3/α4-specific nAChR antagonist DHβE, but not by the α7-specific antagonist α7-BT, indicating the AKT was being activated through PI3K and this was being facilitated through α3 and α4 containing nAChRs (71). Interestingly, phosphorylated AKT was detected in airway epithelial cells and lung tumors from mice treated with NNK, as well as in human lung cancer samples derived from smokers (71); similar results were observed in a study conducted on NSCLC and SCLC cells (75). In the latter study, stimulation of cells with physiologic concentrations of nicotine and NNK induced activation of AKT as well as its downstream substrates GSK-3, FKHR, tuberin, ASK1, 4EBP-1, and SK61; nicotine additionally induced mTOR and MDM2 (75). This study further demonstrated nicotine and NNK could induce proliferation of wild-type cells, but not cells transduced with a mutant AKT, indicating that the proliferation seen in response to these tobacco components is AKT dependent (75).

In this context, a direct link between activation of PI3K/AKT pathway by nicotine and induction of chemoresistance has been proposed. Exposure of multiple NSCLC cells to 1 μmol/L nicotine conferred resistance to apoptosis induced by cisplatin, gemcitabine, and taxol (57). It was found that exposure to nicotine led to an increase in the levels of inhibitor of apoptosis proteins (IAP) XIAP and survivin in a α3β4 nAChR-dependent manner, downstream of AKT signaling (57, 66); interestingly, nicotine did not induce cIAP1 or cIAP2 (57). AKT-mediated phosphorylation is known to prevent the ubiquitination and degradation of XIAP (76); reduced ubiquitination and stabilization of XIAP was observed upon nicotine stimulation, correlating with reduced apoptosis (77). Furthermore, induction of survivin by nicotine occurred at the transcriptional level in an E2F1-dependent fashion, suggesting that exposure to nicotine can confer resistance to apoptosis through multiple mechanisms (57).

NF-κB transcription factor is induced by nicotine and nitrosamines, promoting cell survival. Nicotine has been shown to induce NF-κB via the MAPK pathway, promoting antiapoptotic functions in mesothelialoma cells, mesothelial cells, normal bronchial airway cells, and small airway epithelial cells (44, 60). Similarly, nicotine was shown to confer a survival advantage to NSCLC and SCLC cells treated with paclitaxel, and this occurred with a concomitant increase in NF-κB levels. This study also showed that the ability of nicotine to promote survival was dependent on NF-κB, which was activated downstream of AKT (75). In normal human bronchial epithelial cells, NNK was found to induce nuclear translocation of NF-κB and increase its DNA binding activity within 5 to 10 minutes of stimulation, reaching maximal activation within 30 minutes (60). It was further demonstrated that the activation of NF-κB occurred through the degradation of its negative regulator IκBα, mediated through ERK1/2 phosphorylation (60). In colon cancer cells, NNK has been shown to induce NF-κB in association with proliferation, specifically the p65/RelA subunit, with a concomitant decrease in IκB, which is known to have inverse correlation to NF-κB levels (78). These results strongly suggest that nAChR stimulation enhances NF-κB activity by targeting IκBα for degradation.
Additional survival pathways have also been reported to be induced by nicotine. For example, nicotine stimulation could modulate the levels of Bcl-2 family of anti-apoptotic proteins (79). In SCLC cells, nicotine exerts a protective effect against apoptosis induced by cisplatin by inducing the activation of Bcl-2 (66); in addition, nicotine exposure results in the phosphorylation and inactivation of the pro-apoptotic proteins Bax and Bad, suppressing cell death (57, 79). This inactivation is mediated by the induction of PKC, PKA, MEK, and P13K signaling cascades (9).

In addition, components of the TGF-β signaling cascade are modulated by nicotine to promote survival. It was found that exposure of NSCLC cells and immortalized bronchial epithelial cells to nicotine decreased the expression of SMAD3, resulting in reduced TGF-β-mediated growth inhibition (80). Simultaneously, levels of anti-apoptotic Bcl-2 were increased, resulting in increased cell viability and reduced apoptosis. Interestingly, SMAD3 levels were lower in tumor samples from current smokers compared with never-smokers, and withdrawal of smoking reduced SMAD3 levels (80). Another study conducted on NSCLC cells showed that long-term exposure to nicotine resulted in increased half-maximal inhibitory concentration (IC50) of carboplatin (81). This increase in IC50 was associated with elevated Bcl-2 expression and decreased SMAD3 levels (81); the sensitivity to carboplatin was dependent upon this reciprocal relationship (81). These studies clearly show that exposure to nicotine and activation of nAChR signaling not only promotes the proliferative capacity of lung cancer cells, but also renders them resistant to various apoptotic signals and chemotherapeutic agents.

Additional tumor-promoting functions of nAChRs

In addition to inducing proliferative and survival pathways, nicotine and nAChRs have been found to affect subsequent steps in the growth and metastasis of cancers. nAChRs were found to promote the invasion and migration of cells derived from tumors of the breast, pancreas, or the lungs (10). Nicotine has been found to be a strong inducer of EMT, by suppressing the expression of E-cadherin as well as membrane β-catenin; it could also facilitate the transcriptional induction of mesenchymal genes such as fibronectin and vimentin in multiple cell lines (10). To a certain extent, these events are regulated through ID-1 (34), whereas β-arrestin-1 might also play a part in this process. In a similar fashion, nicotine has been found to promote metastasis by upregulating the expression of various matrix metalloproteinases, including MMP9, MMP14, and MMP15; this induction occurred in an E2F1-dependent manner (50).

It has also been proposed that nicotine and nAChRs can contribute to stem-like functions of tumor-initiating cells, by inducing embryonic stem cell transcription factors including Oct4 and Nanog (82, 83). Nicotine treatment also enhanced the expression of CD44 and BMI-1, and promoted the sphere formation capacity of squamous cell carcinoma cells (83). Similar results have been reported in oral epithelial cells as well, supporting the contention that exposure to nicotine can promote EMT as well as stemness (82). Ongoing studies in our laboratory have also demonstrated the ability of nicotine to promote the self-renewal of stem-like side-population cells from NSCLC; this occurred through the transcriptional induction of stem cell factor (c-Kit ligand) by nicotine (Perumal, D, et al., unpublished data). Although the above studies indicate additional roles for nicotine in promoting EMT and stemness, further studies in this direction would be needed to obtain a complete picture of these events.

nAChRs as potential therapeutic targets for cancer therapy

Given the multifaceted roles of nAChRs in promoting cell proliferation, tumor growth, and metastasis, attempts have been made to target nAChRs to combat smoking induced lung cancers (84, 85). As can be imagined, one major concern about the use of nAChR antagonists is the potential deleterious effect on the neuromuscular system. Furthermore, many nAChR antagonists are known toxins; these include α-cobratoxin and α-bungarotoxin present in snake venom. Interestingly, attempts have been made in mouse models to use these toxins at low doses to combat xenografted tumors. In one such study, mice which were administered α-CbT intravenously at low doses showed no signs of toxic or lethal effects. Furthermore, there were no histological alterations in the brain tissues examined, and there were no observed differences in neurological responses as measured by testing of the autonomic, convulsive, excitability, neuromuscular, sensorimotor, and general motor activity domains of the brain (85). This study also examined the effect of α-CbT and cisplatin on tumors established in mice; the mice which received cisplatin had 16% improved survival compared with the control mice whereas mice which received 0.12 ng/kg of α-CbT had a 90% improved survival compared with the controls, probably because of increased apoptosis of tumor cells (85). In contrast to these observations, a study on 5 lung cancer cell lines reported conflicting results (86). This study measured tumor growth in in vivo orthotopic mouse models using the same protocols and doses as the prior mentioned study, yet found no significant reduction of tumor growth or survival of mice treated with 0.12 ng/kg of either long or short chain α-CbT as compared with controls; and in the case of the short chain α-CbT, there was an increase in tumor growth which did not reach statistical significance (86). Interestingly, in the study which found no response to α-CbT, all of the mice in had to be sacrificed at day 28 due to tumor burden, whereas in the initial study that reported a response to α-CbT the mice were followed up to 170 days. It is not clear why the 2 studies reported conflicting results; however, it should be noted that a number of additional studies have reported decreased tumor growth in response to α-CbT, although the experimental conditions varied in each study (87–90). These results raise the intriguing possibility that targeting nAChRs, specifically α7 nAChR, might be a viable strategy to combat NSCLC, but a significant amount of additional studies would be needed to pursue this further. Given the potential toxicity of α7 antagonists, and given the neuronal function of these
receptors, targeting the downstream effectors of nAChRs might be an alternate approach that is worth considering.

**Summary and Conclusions**

Tobacco smoke is the single greatest preventable risk factor for cancer (2), yet is still responsible for an estimated 160,848 cancer-related deaths each year in the United States, alone globally. The current literature has shed light upon the multiple molecular mechanisms by which components of tobacco smoke can initiate tumor formation, impact cell-cycle progression and proliferation, and promote tumor progression in multiple cancer types. In a review of 10 studies, it was found that people who continue to smoke after diagnosis of early stage lung cancer nearly double their risk of dying (91), and cessation of smoking after diagnosis improves multiple aspects of lung cancer including decreased risk of second tumors, increased overall well-being, improved immune response, and increased response to chemotherapeutic agents (69). There are a number of smoking cessation aids available, including varenicline, bupropion as well as various nicotine replacement therapy (NRT) agents.

Given that nicotine has tumor-promoting properties, concerns have been raised about the deleterious effects of NRT on cancer therapy and survival. There have been limited efforts made to examine how exposure to nicotine through NRT products affects tumor growth or normal physiology including immune function in human subjects. The advantage of NRT is that although tobacco smoke contains literally hundreds of carcinogens, these are absent in NRT products, including varenicline, bupropion as well as various nicotine replacement therapy (NRT) agents.

For the treatment of tobacco-related cancers in the future.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Disclaimer**

Our apologies to the authors whose work could not be cited because of space limitations.

**Authors’ Contributions**

Writing, review, and/or revision of the manuscript: C. Schaal, S.P. Chellappan

Study supervision: S.P. Chellappan

**Acknowledgments**

The authors thank S. Pillai and other lab members for critical comments.

**Grant Support**

Studies in the Chellappan lab are supported by the Grants CA127725 and CA139612 from the NCI.

Received October 8, 2013; revised December 5, 2013; accepted December 5, 2013; published online January 7, 2014.

**References**

Nicotine-Mediated Cell Proliferation and Tumor Progression in Smoking-Related Cancers

Courtney Schaal and Srikumar P. Chellappan


Updated version  Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-13-0541

Cited articles  This article cites 91 articles, 32 of which you can access for free at: http://mcr.aacrjournals.org/content/12/1/14.full.html#ref-list-1

Citing articles  This article has been cited by 12 HighWire-hosted articles. Access the articles at: /content/12/1/14.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.